PitchBook：2025年一季度医疗技术公共报表和估值指南报告（英文版）

Medtech holds up amid market turmoil: The medtech sector delivered mixed results in Q1 2025, with about half of large public companies posting share price gains. Still, median stock returns for the sector performed better than the overall market, as the S&P 500 fell 4.6% in the quarter and the Nasdaq index declined 10.4%. Volatility was most pronounced in the life sciences segment: Tempus AI gained nearly 43% before relinquishing those gains in April, while Illumina saw the steepest decli